VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapies for dermatology. The company is headquartered in Bridgewater, New Jersey.
| Revenue (TTM) | 454,000 |
| Gross Profit (TTM) | 454,000 |
| EBITDA | $-24.34M |
| Operating Margin | -4437.00% |
| Return on Equity | -63.20% |
| Return on Assets | -37.00% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $0.83 |
| Price-to-Book | 0.91 |
| Price-to-Sales (TTM) | 49.32 |
| EV/Revenue | 10.04 |
| EV/EBITDA | 1.84 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -57.40% |
| Shares Outstanding | $33.35M |
| Float | $32.55M |
| % Insiders | 4.34% |
| % Institutions | 41.71% |
Volatility is currently contracting